Enzolytics Inc ENZC

Enzolytics Inc OTC
No trades
Upcoming Earnings
Market Cap
Div Yield
Upcoming Earnings
Market Cap
Div Yield

ENZC Chart

Trade ENZC with trusted brokers on TradingView Open account
Enterprise Value/EBITDA, TTM
Enterprise Value, FQ
Market Cap — Basic
Number of Employees
Number of Shareholders
Price/Earnings, TTM
Price/Revenue, TTM
Price/Book Ratio, FY
Price/Sales Ratio, FY
Balance Sheet
Current Ratio, FQ
Debt to Equity, FQ
Net Debt, FQ
Quick Ratio, FQ
Total Assets, FQ
Total Debt, FQ
Operating Metrics
Return on Assets, TTM
Return on Equity, TTM
Return on Invested Capital, TTM
Revenue per Employee, TTM
Price History
Average Volume (10 day)
Beta - 1 Year
Price - 52 Week High
Price - 52 Week Low
Dividends Paid, FY
Dividends per Share, FY
Expected Annual Dividends
Dividends Yield
Net Margin, TTM
Gross Margin, TTM
Operating Margin, TTM
Pretax Margin, TTM
Income Statement
Basic EPS, Net Income
Earnings per Share, Basic, TTM
Gross Profit, FY
Last Annual EPS
Last Annual Revenue, FY
Net Income, FY
Total Revenue, FY
Free Cash Flow, TTM


Sector: Health Technology
Industry: Biotechnology
Enzolytics, Inc. is a biotechnology company, which engages in the development and commercialization of drugs for infectious disease treatments. The company’s all-human monoclonal antibodies target and neutralize human immunodeficiency virus, and are being employed to produce anti-SARS-CoV-2 monoclonal antibodies for treating COVID-19. Its proprietary therapeutics is also being tested against Hepatitis A, B and C, Rheumatoid Arthritis, certain forms of cancer, rabies, influenza A and B, tetanus, and diphtheria. Enzolytics was founded in 2007 and is headquartered in Plano, TX.